228 related articles for article (PubMed ID: 17254349)
1. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells.
Ramakrishna V; Vasilakos JP; Tario JD; Berger MA; Wallace PK; Keler T
J Transl Med; 2007 Jan; 5():5. PubMed ID: 17254349
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.
He LZ; Weidlick J; Sisson C; Marsh HC; Keler T
Cell Mol Immunol; 2015 Nov; 12(6):719-28. PubMed ID: 25345808
[TBL] [Abstract][Full Text] [Related]
3. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta.
He LZ; Ramakrishna V; Connolly JE; Wang XT; Smith PA; Jones CL; Valkova-Valchanova M; Arunakumari A; Treml JF; Goldstein J; Wallace PK; Keler T; Endres MJ
Clin Cancer Res; 2004 Mar; 10(6):1920-7. PubMed ID: 15041707
[TBL] [Abstract][Full Text] [Related]
4. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
[TBL] [Abstract][Full Text] [Related]
5. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J; Kluger H; Tejwani S; Green J; Ramakrishna V; Crocker A; Vitale L; Yellin M; Davis T; Keler T
Sci Transl Med; 2014 Apr; 6(232):232ra51. PubMed ID: 24739759
[TBL] [Abstract][Full Text] [Related]
6. Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation.
van Liempt E; van Vliet SJ; Engering A; García Vallejo JJ; Bank CM; Sanchez-Hernandez M; van Kooyk Y; van Die I
Mol Immunol; 2007 Apr; 44(10):2605-15. PubMed ID: 17241663
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
8. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
9. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
[TBL] [Abstract][Full Text] [Related]
10. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization.
Singh SK; Streng-Ouwehand I; Litjens M; Kalay H; Burgdorf S; Saeland E; Kurts C; Unger WW; van Kooyk Y
Eur J Immunol; 2011 Apr; 41(4):916-25. PubMed ID: 21400496
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
[TBL] [Abstract][Full Text] [Related]
12. Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells.
Lee JS; Kim SG; Kim HK; Lee TH; Jeong YI; Lee CM; Yoon MS; Na YJ; Suh DS; Park NC; Choi IH; Kim GY; Choi YH; Chung HY; Park YM
J Cell Physiol; 2007 Feb; 210(2):385-97. PubMed ID: 17058260
[TBL] [Abstract][Full Text] [Related]
13. Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Schmitt S; Tahk S; Lohner A; Hänel G; Maiser A; Hauke M; Patel L; Rothe M; Josenhans C; Leonhardt H; Griffioen M; Deiser K; Fenn NC; Hopfner KP; Subklewe M
Front Immunol; 2020; 11():602802. PubMed ID: 33281829
[TBL] [Abstract][Full Text] [Related]
14. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
15. An adjuvant role of in situ dendritic cells (DCs) in linking innate and adaptive immunity.
Shimizu K; Fujii S
Front Biosci; 2008 May; 13():6193-201. PubMed ID: 18508653
[TBL] [Abstract][Full Text] [Related]
16. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells.
Chen XZ; Mao XH; Zhu KJ; Jin N; Ye J; Cen JP; Zhou Q; Cheng H
Arch Dermatol Res; 2010 Jan; 302(1):57-65. PubMed ID: 19578865
[TBL] [Abstract][Full Text] [Related]
17. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.
Boks MA; Ambrosini M; Bruijns SC; Kalay H; van Bloois L; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Oct; 216():37-46. PubMed ID: 26151293
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
19. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
20. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
